HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nicolas Willand Selected Research

Ethionamide (Trecator-SC)

3/2024Crystal structure of the Mycobacterium tuberculosis VirS regulator reveals its interaction with the lead compound SMARt751.
1/2022The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.
1/2020Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
1/2019A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR.
1/2019A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation.
11/2018Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
5/2018Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
12/2017New active leads for tuberculosis booster drugs by structure-based drug discovery.
3/2017Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
1/2017Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nicolas Willand Research Topics

Disease

16Tuberculosis (Tuberculoses)
04/2024 - 05/2009
3Infections
01/2020 - 03/2017
1COVID-19
03/2022
1Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
01/2019
1Extensively Drug-Resistant Tuberculosis
11/2013
1Acquired Immunodeficiency Syndrome (AIDS)
05/2012
1Bacterial Infections (Bacterial Infection)
05/2012
1Coinfection
05/2012

Drug/Important Bio-Agent (IBA)

13Ethionamide (Trecator-SC)FDA Link
03/2024 - 04/2012
4ProdrugsIBA
03/2024 - 12/2017
2Moxifloxacin (Avelox)FDA Link
04/2024 - 05/2012
2LigandsIBA
03/2024 - 04/2012
2Antitubercular AgentsIBA
10/2023 - 05/2012
2Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 11/2018
1Fatty Acid Synthases (Fatty Acid Synthase)IBA
02/2023
1Anti-Infective Agents (Microbicides)IBA
03/2022
1Mixed Function Oxygenases (Monooxygenases)IBA
01/2022
1OxadiazolesIBA
01/2020
1A-factor (Streptomyces)IBA
01/2019
1CyclodextrinsIBA
01/2019
1Proteins (Proteins, Gene)FDA Link
01/2019
1SMARt-420IBA
03/2017
1Metronidazole (Metric)FDA LinkGeneric
05/2012
1Linezolid (Zyvox)FDA Link
05/2012
1Gatifloxacin (Zymar)FDA Link
05/2012
1DNA (Deoxyribonucleic Acid)IBA
04/2012

Therapy/Procedure

3Therapeutics
05/2018 - 05/2009
1Drug Therapy (Chemotherapy)
11/2018